Vol. 3 No. 9 (2026), Articles
Vol. 3 No. 9 (2026)

NANOMATERIALLAR VA MOLEKULYAR BIOMARKERLARNING ALSGEYMER KASALLIGIDA PREKLINIK AHAMIYATI.

Articles
Published 2026-01-18
Isaqov Jahongir Inomjon o‘g‘li
Namangan Davlat Unversiteti “Klinik fanlar kafedrasi” stajyor-oqituvchisi
Islomjon Madaminov Qurbonali o‘g‘li
University of Business and Science “Umumkasbiy fanlar kafedrasi” o‘qituvchisi,
Bunyodjon Mamatvaliyev Rahmonali o‘g‘li
University of Business and Science “Tibbiyot kafedrasi” o‘qituvchisi,
Nosirov Temurbek Isroiljon o'g'li
University of Business and Science “Tibbiyot kafedrasi” o‘qituvchisi,
PDF

Keywords

Alsgeymer kasalligi, molekulyar biomarkerlar, amiloid‑β, fosforillangan tau, nanomateriallar, erta diagnostika, bioinformatika

Abstract

Alsgeymer kasalligi (AK) neyrodegenerativ buzilishlar orasida eng keng tarqalgan bo‘lib, xotira va kognitiv qobiliyatlarning pasayishi bilan kechadi. Erta aniqlash terapevtik aralashuv va profilaktik strategiyalarni ishlab chiqishda muhim ahamiyatga ega. Ushbu maqola molekulyar biomarkerlar va nanomateriallarning AKni erta aniqlashdagi diagnostik salohiyatini tizimli tarzda ko‘rib chiqadi. Amiloid‑β (Aβ) va fosforillangan tau (p‑tau) oqsillari klinik belgilar paydo bo‘lmasdan oldin kasallikni aniqlash imkonini beruvchi ishonchli indikatorlar sifatida ajralib turadi. Nanomateriallar yordamida diagnostika jarayoni sezgirligi oshirilgan va klinik qo‘llanilish uchun istiqbolli strategiyalar taklif etiladi. Shu bilan birga, bioinformatik yondashuvlar va multi-biomarker paneli erta diagnostika samaradorligini yanada oshiradi.

PDF

References

1. Jack, C.R., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562.

2. Selkoe, D.J. (2019). Alzheimer disease and aducanumab: adjusting expectations. Nature Reviews Neurology, 15(7), 365–366.

3. Hampel, H., et al. (2021). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 17, 10–24.

4. Blennow, K., Zetterberg, H. (2018). Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med, 284(6), 643–663.

5. Villemagne, V.L., et al. (2013). Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease. JAMA Neurol, 70(6), 751–761.

6. Liu, L., et al. (2020). Nanotechnology-based strategies for early diagnosis of Alzheimer’s disease. ACS Nano, 14(9), 11458–11476.

7. Cummings, J., et al. (2020). Alzheimer’s disease drug development pipeline: 2020. Alzheimer’s & Dementia, 6, e12050.

8. Lista, S., et al. (2022). Multi-biomarker panels and AI(SI) in early Alzheimer’s detection. Frontiers in Neuroscience, 16, 845612.